MindMed is a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, with a particular focus on psychiatry, addiction, pain and neurology. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative drug candidates, with and without acute perceptual effects, targeting the serotonin, dopamine and acetylcholine systems.
MindMed trades on the NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED.
MindMed proudly partners with the Liechti Lab of Professor Dr. Matthias Liechti, the world-leading psychedelics pharmacology and clinical research group at University Hospital Basel in Switzerland. This collaboration includes the exclusive rights to data, compounds, and patents associated with the research on lysergic acid diethylamide (LSD) and other psychedelic compounds.
MindMed is funding the launch of a clinical training program at NYU Langone Health that aims to facilitate the recruitment and training of more psychiatrists and clinical investigators in delivering psychedelic assisted therapies and psychedelic inspired medicines. In preparation for future deployment of these medicines, it is imperative to get psychedelic substances in front of clinical researchers and give them the resources they need to help clarify the path forward.
The NYU Langone Health Psychedelic Medicine Research Training Program will provide support, training, mentorship, and research funding necessary and will be managed by Principal Investigator Michael Bogenschutz, M.D., an expert in clinical trials research and the primary investigator leading the effort for approval of psilocybin-assisted psychotherapy for Alcohol Use Disorder by the FDA. The program will be directed by Stephen Ross, M.D., a world leader in advancing research on psychedelic medicine and a prominent addiction psychiatrist.
MindMed is collaborating with Maastricht University in the Netherlands to undertake a Phase 2a clinical trial for microdosing LSD for adult ADHD. The proof-of-concept study is planned to take place at two trial sites, including Maastricht University. The principal investigator of the study is Kim Kuypers, one of the world’s top psychedelics microdosing clinical researchers. The trial is scheduled to begin at the end of 2020.